Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01791985 | AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)(RADICAL) | completed | Phase 1 / Phase 2 | 52 | Imperial College LondonOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02506556 | Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer(PIKNIC) | completed | Phase 2 | 38 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 |
| Aug 16, 2022 |
| clinicaltrials |
| NCT04075604 | A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer(CheckMate 7A8) | completed | Phase 2 | 23 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 10, 2022 | clinicaltrials |
| NCT01989780 | Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer(BOOSTER) | completed | Phase 2 | 160 | Japan Breast Cancer Research GroupOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT00468715 | Bicalutamide in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02657343 | An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. | completed | Phase 1 / Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2022 | clinicaltrials |
| NCT02177175 | Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification | completed | Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT02282345 | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer | completed | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT01990209 | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | completed | Phase 2 | 71 | SCRI Development Innovations, LLCOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT01082211 | Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery | completed | Phase 2 | 65 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT03184090 | Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC(BioPER) | completed | Phase 2 | 33 | MedSIROTHER | 2 | Jun 21, 2022 | clinicaltrials |
| NCT02379247 | BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer | completed | Phase 1 / Phase 2 | 43 | Priyanka SharmaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT03948477 | Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy(PantoCIN) | completed | Phase 2 | 160 | University of Auckland, New ZealandOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT02789657 | Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | completed | Phase 2 | 32 | Brown UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT02536794 | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT00676663 | Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer(ENCORE301) | completed | Phase 2 | 130 | Syndax PharmaceuticalsINDUSTRY | 5 | May 11, 2022 | clinicaltrials |
| NCT01904903 | Cardiac Safety Study in Patients With HER2 + Breast Cancer(SAFE-HEaRt) | completed | Phase 2 | 31 | Medstar Health Research InstituteOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02698891 | Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer | completed | Phase 2 | 127 | Dana-Farber Cancer InstituteOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT01033032 | Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 78 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT00248703 | Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow | completed | Phase 2 | 1,128 | Oslo University HospitalOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT01293682 | Effects of High Dose Calcitriol in Breast Cancer Patients | completed | Phase 2 | 12 | University of RochesterOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03254654 | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03628066 | Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer | completed | Phase 2 | 24 | NSABP Foundation IncNETWORK | 2 | Apr 20, 2022 | clinicaltrials |
| NCT02771353 | The HeartSpare Plus 1B Trial | completed | Phase 2 | 39 | Royal Marsden NHS Foundation TrustOTHER | 0 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT01204242 | IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: | completed | Phase 2 | 78 | University of VirginiaOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT02384239 | A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | completed | Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02659514 | Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer | completed | Phase 2 | 67 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02729701 | Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation | completed | Phase 2 | 28 | University of Kansas Medical CenterOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT01831076 | Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors | completed | Phase 2 | 36 | University of Colorado, DenverOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT00566618 | Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis | completed | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT02387099 | Dose EScalation Induction of EvERolimus(Desiree) | completed | Phase 2 | 156 | GBG Forschungs GmbHOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02000882 | STAR Cape+BKM120 MBC With Brain Met | completed | Phase 2 | 10 | US Oncology ResearchINDUSTRY | 1 | Feb 7, 2022 | clinicaltrials |
| NCT03243838 | Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer(LANCET) | completed | Phase 2 | 31 | Guangdong Provincial People's HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02297412 | Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel | completed | Phase 2 | 47 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT02418689 | Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens | completed | Phase 2 | 106 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Jan 20, 2022 | clinicaltrials |
| NCT02296801 | A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer(PALLET) | completed | Phase 2 | 307 | NSABP Foundation IncNETWORK | 3 | Jan 13, 2022 | clinicaltrials |
| NCT01988571 | Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT) | completed | Phase 2 | 279 | Wake Forest University Health SciencesOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT03608865 | Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing | completed | Phase 2 | 30 | Yonsei UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT01849250 | Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Dec 28, 2021 | clinicaltrials |
| NCT03316586 | A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT00952692 | Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 12 | Michael Morse, MDOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02595372 | Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy | completed | Phase 2 | 42 | Kathy MillerOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04143282 | Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment | completed | Phase 2 | 250 | Hager salah el dinOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT00629499 | Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer | completed | Phase 2 | 63 | SCRI Development Innovations, LLCOTHER | 1 | Nov 24, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Aug 22, 2022source: clinicaltrials